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doi:10.1016/j.jtcvs.2007.12.085Objective: The TNM classification has been widely used as a guide for estimating
prognosis and is the basis for treatment decisions on various solid tumors. The Inter-
national Association for the Study of Lung Cancer Staging Committee has proposed
a new staging system for the next revision scheduled in 2009. However, its validity
has not been established fully. Here we assessed its utilities and drawbacks.
Methods: We reviewed 1556 consecutive patients with non–small cell lung cancers
who underwent pulmonary resection in our institution and reviewed their survival
characteristics based on the 2009 system compared with the current (1997) system.
Results: The numbers of patients with stage IIA disease increased remarkably when
using the 2009 system because of the reclassification of stages IB and IIB. Although
the 5-year survival rates of the patients with stage IB and IIA disease in the 1997 sys-
tem showed no difference with the 2009 system, the survival rates of patients with
stage IB disease was 68.0%, which is better than that of patients with stage IIA disease
(57.6%). The patient survival curves showed stepwise deterioration as the numbers
increased, except for patient with stage IV disease.
Conclusions: Our study supported the proposal for this new staging system. Com-
pared with the 1997 system, the 2009 system appears to be superior in separating stage
IB and IIA disease and provides an even distribution among the stage groupings,
although it is slightly complicated. The survival characteristics of 1556 resected cases
in this single Japanese institution validated the proposed 2009 system.
T
he TNM classification of cancers proposed by the Union Internationale Contre
le Cancer has been widely accepted as a guide for estimating patient prognosis
and is the basis for treatment decisions in practice. In lung cancer the first edi-
tion of the TNM classification was published in 1968, and it has been revised 5 times:
in 1974 (second edition), 1978 (third edition), 1987 (fourth edition), 1997 (fifth edi-
tion), and 2002 (sixth edition). The 1997 revision has undergone an extensive correc-
tion for many deficiencies in the old staging system.1 The sixth and current edition
from 2002 is a minor revision of the fifth edition, and the next revision is scheduled
in 2009.
Thus the staging system has been revised many times to make it better. However,
there are still some controversies and proposals for revision in the current edition. In
a large-scale retrospective study of non–small cell lung cancer (NSCLC) performed
by the Japanese Joint Committee of Lung Cancer Registry, no difference in prognosis
between stage IB and IIA disease was seen in either clinical or pathologic settings.2
Many investigators reported similar discordant results concerning stage IB and IIA
disease.3-6 In addition, although a satellite tumor nodule in the primary lobe is defined
as T4 in the current system, some suggested that it might behave more favorably than
in patients with another subgroup of T4.7 As a result, distinguishing the prognoses ofThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 5 1343
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patients with stage IIIA and IIIB disease is sometimes un-
clear.5,8,9 To correct these controversies, the International
Association for the Study of Lung Cancer (IASLC) Staging
Committee proposed a new staging system for the next revi-
sion (summarized in Table 1 and Figure 1).10-13
The purpose of this retrospective study was to review the
survival characteristics of patients based on the new staging
system proposed by the IASLC. We studied 1556 consecu-
tive patients who underwent pulmonary resection in a single
institution, Aichi Cancer Center Hospital. We also discuss
the utilities and drawbacks of the new staging system.
Materials and Methods
Patient Cohort
Approval for this study was obtained from and the need for
individual patient consent was waived by the institutional review
board. During a 21-year period from 1982 through 2002, 1556 pa-
tients with primary NSCLCs were enrolled in this study. The
patients with pathologic stage IA to IV disease, including clinical
patients with N2 disease, underwent surgical intervention. All pa-
tients underwent surgical resection with nodal dissection at the
Aichi Cancer Center Hospital and were followed up for at least
5 years or until death. Data extracted from each patient’s medical re-
cord included age, sex, smoking history, tumor histology and loca-
tion, adjuvant and induction therapies, date of last follow-up, and
death from any cause. Themedian follow-up periodwas 104months.
The patients comprised 1021 (66%) men and 535 (34%) women,
ranging in age from 24 to 89 years (mean 6 standard deviation,
62 6 9.8 years). There were 977 (63%) adenocarcinomas, 429
(28%) squamous cell carcinomas, 87 (5%) large cell carcinomas,
and 63 (4%) other types of cancers. Evaluation of pN classification
was determined from pathologic examination of resected specimens,
including determination of the location and number of lymph nodes
examined and the number found to be positive.
Preoperative therapy was performed in 52 (3%) patients. They
comprised 16 patients with clinical stage IIB, 25 with stage IIIA,
8 with stage IIIB, and 2 with stage IV disease. Among them, 27
and 8 patients underwent chemotherapy or radiotherapy, and 16 pa-
tients underwent chemoradiotherapy. Postoperative adjuvant che-
motherapy was administered to only 10 (0.6%) patients with stage
IB or higher disease in this cohort.
New Staging System
Changes in the new TNM staging system for lung cancer proposed
by the IASLC are listed in Table 1. Concerning the T descriptor, the
IASLC proposed a subclassification of the current T2 tumors ac-
cording to tumor size: those larger than 3 cm to 5 cm or less or clas-
sified as T2 based on another factor and 5 cm or less are defined as
T2a, those larger than 5 cm to 7 cm or less are defined as T2b, and1344 The Journal of Thoracic and Cardiovascular Surgery c Nthose larger than 7 cm are defined as T3. An additional tumor nodule
in the same lobe is classified as T3 and in the ipsilateral different
lobe as T4 but as M1a if it is in the contralateral lung. In addition,
pleural dissemination is classified as M1a. Concerning the N classi-
fication, the IASLC supported the continued use of the current N0,
N1, N2, and N3 stage descriptors.12 In the stage grouping the IASLC
proposed to reclassify T2a N1 (current IIB) and T2b N0 (current IB)
collectively as stage IIA disease and T4 N0 and T4 N1 (current IIIB)
as stage IIIA disease.
Survival Analyses
The Kaplan–Meier method was used to plot the survival curves, and
the log-rank test was used to evaluate differences between sub-
groups. To evaluate the significance of the new classification as
an independent prognostic factor, we performed multivariate analy-
sis by using the Cox proportional hazards model with 2 different
TABLE 1. Summary of the proposal for changes to the sixth
edition of the TNM classification10
Tumor size
 Reclassify T2 tumors .7 cm as T3
 Subclassify:
 T1 as
— T1a (#2 cm) or
— T1b (.2 cm to #3 cm); and
 T2 as
— T2a (.3 to #5 cm or T2 by other factor and #5 cm) or
— T2b (.5 to #7 cm)
Separate tumor nodule
 Reclassify T4 tumors with additional nodules in the lung
(primary lobe) as T3
 Reclassify M1 with additional nodules in the ipsilateral
lung (different lobe) as T4
 Subclassify M1 with additional nodules in the contralateral
lung as M1a
M factor
 Reclassify pleural dissemination (malignant pleural or
pericardial effusions, pleural nodules) from T4 to M1a
 Subclassify M1 with distant metastases (outside the lungs
or pleura) as M1b
Stage grouping
 Reclassify T2a N1 tumors (#5 cm) as stage IIA (from IIB)
 Reclassify T2b N0 tumors (.5–7 cm) as stage IIA (from IB)
 Reclassify T4 N0 and T4 N1 tumors as stage IIIA (from IIIB)
Figure 1. The stage grouping according to the proposed system by
the IASLC.10ovember 2008
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tem) and the other being the proposed one (the 2009 system). Trend
P values were assessed by using score tests. Statistical calculations
were performed with a statistical package (StatView version 5.0;
SAS Institute, Inc, Cary, NC).
Results
Distribution of Pathologic Stage
According to the 1997 system, patientswere distributed as fol-
lows: stage IA, n5 448 (28.8%); stage IB, n5 368 (23.7%);
stage IIA, n 5 44 (2.8%); stage IIB, n 5 194 (12.5%); stage
IIIA, n5 317 (20.4%); stage IIIB, n5 122 (7.8%); and stage
IV, n 5 63 (4.0%). When applied to the 2009 system, they
were distributed as follows: stage IA, n5 448 (28.8%); stage
IB, n5 278 (17.9%); stage IIA, n5 175 (11.2%); stage IIB,
n 5 155 (10.0%); stage IIIA, n 5 378 (24.3%); stage IIIB,
n5 41 (2.6%); and stage IV, n5 81 (5.2%; Figure 2). Com-
paring the 2 distributions, the proportion of patients with stage
IIA disease was increased remarkably by the reclassification
of patients with stage IB and IIB disease. Sixty patients with
current stage IB disease were redefined as having new stage
T2bN0M0disease, and 71 patients with current stage IIB dis-
ease were redefined as having new stage T2a N1 M0 disease
and shifted to a new stage, IIA. One hundred thirty-seven
patients were shifted to a higher stage with the 2009 system,
mostly from IB to IIA (n 5 60). On the other hand, 139 pa-
tients were shifted to a lower stage, and most of these were
from stages IIB to IIA (Table 2).
Survival Analysis
Survival curves and the 5-year survival rates according to the
1997 and 2009 staging systems are shown in Figure 3. The
Figure 2. Distribution of the patients according to the current and
proposed new stage groupings. The proportion of patients with
stage IIA disease increased remarkably because they were
reclassified from current stages IB and IIB.The Journal of Thora5-year survival rates of the patients with current stage IB
and IIA disease were 64.9% and 65.9%, respectively, in
this cohort, being almost identical (P 5 .54). With respect
to the 2009 system, the survival curves showed stepwise de-
terioration as the stage increased, except for patients classed
as having stage IV disease. The 5-year survival rate of pa-
tients classed as having stage IB disease was 68.0%, which
was better than that of those with stage IIA disease (57.6%;
P 5 .09; Figure 3, B). We analyzed the patient survival
TABLE 2. Comparison between current and proposed
pathologic stages
2009 system
1997 system IA IB IIA IIB IIIA IIIB IV Total
IA 448 0 0 0 0 0 0 448
IB 0 278 60 30 0 0 0 368
IIA 0 0 44 0 0 0 0 44
IIB 0 0 71 114 10 0 0 195
IIIA 0 0 0 0 316 0 0 316
IIIB 0 0 0 11 38 36 37 122
IV 0 0 0 0 14 5 44 63
Total 448 278 175 155 378 41 81 1556
Figure 3. Survival curves for patient subgroups stratified accord-
ing to stage groupings. The 5-year survival rate and the number of
patients in each subgroup are indicated. A, With regard to the cur-
rent staging system, no survival difference was observed between
patients with stage IB and IIA disease (P5 .54). B, With regard to
the proposed system, the survival curves showed significant step-
wise deterioration as the numbers increased, except for patients
with stage IV tumors. There was a difference in the prognoses of
patients with stage IB and IIA disease, although this was not
statistically significant (P 5 .09).cic and Cardiovascular Surgery c Volume 136, Number 5 1345
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difference between T1a and T1b tumors (P5 .35, Figure 4).
Concerning satellite tumor nodules, 22 patients who were
classified as having T4 tumors only because of their satellite
tumor nodules showed significantly better survival than that
of other patients with T4 tumors. The 5-year survival rate of
these 22 patients was 36%, whereas it was 17% in the other
T4 group (P 5 .038).
Multivariate analysis with the Cox proportional hazard
model was performed to evaluate the significance of the stage
groupings, including the following variables: age, sex, histol-
ogy, and 1997 and 2009 stage grouping. Each stage grouping
was tested independently in the same combination with other
variables. The result is summarized in Table 3. Hazard ratios
for stage IB and IIA disease in the 1997 system referred to as
stage IA disease were 1.83 and 1.80, respectively, versus 1.72
and 2.17 in the 2009 system. Among the clinicopathologic
variables analyzed, each stage grouping was an independent
prognostic factor.
Discussion
The staging system for cancer according to TNM classifica-
tion is an accepted principle used by oncologists. It serves
many objectives: to give some indication of prognosis, to
plan treatments, to evaluate the results of treatments, to
Figure 4. Survival curves for patient subgroups stratified accord-
ing to T descriptors. The 5-year survival rate and the number of pa-
tients in each subgroup are indicated. A, With regard to the
current staging system, the survival curves showed significant
stepwise deterioration as the numbers increased. B, For the
proposed system, there was no significant prognostic difference
between the new T1a and T1b stages (P 5 .35).1346 The Journal of Thoracic and Cardiovascular Surgery c Nofacilitate the exchange of information among institutions,
and to contribute to the continuing investigation of human
cancer.14,15 Therefore the system should be revised accord-
ing to the prognosis of patients with relatively homogeneous
backgrounds. For lung cancers, the American Joint Commit-
tee on Cancer and Union Internationale Contre le Cancer
adopted several revisions to the 1986 stage classification,
changes that were later published by Mountain1 in 1997 as
the fifth edition. For the next revision scheduled in 2009,
the IASLC Staging Committee has proposed a new staging
system based on a well-organized, large international data-
base covering more than 80,000 patients with lung can-
cers.10-13 In the present study we attempted to assess the
validity of the proposed revision.
One of the most important aims for the next revision is to
correct the similar survival rates of patients with stage IB and
IIA disease, which is partly caused by the relatively few pa-
tients with stage IIA disease, as reported by many investiga-
tors: 1.4% in Mountain’s series,1 3.5% in the Japanese
series,2 3.7% in the series by Naruke and colleagues,6 and
4.4% in the series by Inoue and associates.3 Mountain had al-
ready reported the similar prognoses for patients with stage
IB and IIA disease: 57% and 55%, respectively.1 In our co-
hort no survival difference was observed between patients
with stage IB or IIA disease (64.9% and 65.9%, respectively),
and patients with stage IIA disease accounted for only 2.8%
of the whole. According to this proposal, the number of pa-
tients categorized as having stage IIA disease increased to
175 (11%) from 44 (2.8%) in our cohort. The survival anal-
ysis showed differences between the prognoses of patients
with stage IB and IIA disease, although the difference was
not statistically significant (P 5 .09).
Other overlapping prognoses of patients with neighbor-
ing stages were seen between stages IIIB and IV in this
study. In the 2009 system an additional tumor nodule in
the same lobe is classified as T3 and pleural dissemination
TABLE 3. Comparison of hazard ratios by means of 2
multivariate analyses with the Cox hazard model
1997 staging system 2009 staging system
Hazard ratio 95% CI Hazard ratio 95% CI
IA 1.00 1.00
IB 1.83 1.46–2.30 1.72 1.35–2.20
IIA 1.80 1.13–2.85 2.17 1.67–2.83
IIB 3.11 2.42–3.99 3.16 2.43–4.11
IIIA 4.68 3.77–5.81 4.96 4.02–6.12
IIIB 7.34 5.64–9.55 10.60 7.35–15.4
IV 6.50 4.66–9.07 7.35 5.46–9.89
Trend P , .0001 Trend P , .0001
Each stage grouping was tested independently in the same combination
with other variables. Other variables are as follows: age (,62/$62 years),
sex (male/female), and histology (squamous/nonsquamous). CI, Confidence
interval.vember 2008
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creased from 122 (7.8%) to 41 (2.6%). The worse 5-year
survival rates than seen with current stage IIIB disease
(12.2% and 19.6%) seem to be because of the shifting of pa-
tients who behaved more favorably than other subgroups of
patients with T4 tumors to the earlier stages. Because this
retrospective study only included resected cases and most
patients with advanced stages are generally not candidates
for surgical intervention, the patients with stage III and IV
disease in this study did not represent the whole population
of these stage groups.
In the 1997 TNM classification, a satellite tumor nodule in
the primary lobe is defined as T4. However, some investiga-
tors suggested that patients with a satellite tumor nodule in
the primary lobe might behave more favorably than patients
with other subgroups of T4 tumors.7,16 Because 22 patients
with satellite tumor nodules in the same lobe showed signif-
icantly better survival than the other patients with T4 tumors
in this study, the 2009 system seems to be appropriate. Usu-
ally, any satellite tumor nodule in a different lobe is regarded
as metastatic, but it remains arguable whether the nodule is
really a metastatic lesion or a synchronous lung neoplasm.
However, it is very difficult to distinguish them by means
of preoperative evaluations with imaging studies in clinical
practice.
Many investigators have reported the effects of tumor size
on stage, curability, and patient survival.9,17-19 In the 2009
system current T1 tumors should be divided into T1a (tumors
#2 cm in greatest dimension) and T1b (tumors .2 cm but
#3 cm) tumors, although the subclassification would not
be reflected in stage grouping.10,11 In this study we analyzed
the survival characteristics according to the T descriptors and
found no prognostic difference between the new T1a and T1b
classifications (Figure 3). One possible reason might be the
limited value of the evaluation of invasiveness by tumor
size alone. Recent clinical use of high-resolution computed
tomographic analysis has greatly advanced the diagnosis of
small lesions of the peripheral lung. Bronchioloalveolar car-
cinoma (BAC), which is detected as such a small lesion, is the
noninvasive form of an adenocarcinoma and often included
in the smaller T category. In the revised World Health
Organization histologic classification, a BAC is classified
as a noninvasive carcinoma with no evidence of stromal,
vascular, or pleural invasion. The excellent prognosis for
patients after surgical resection of BACs is already well rec-
ognized.20 In the present study the histologic category as an
adenocarcinoma might have included a BAC, and its prog-
nostic significance was not demonstrated independently.
Asamura and coworkers21 suggested that these noninvasive
BACs should be newly termed as Ti and excluded from the
T1 category. On the other hand, hilar or mediastinal nodal
metastases have been found even in patients with adenocar-
cinomas of 1.0 cm or less.22,23Moreover, in our cohort lymph
node involvement had been found in 3 patients among 18The Journal of Thoradenocarcinomas measuring 1 cm or less in diameter
(detailed data not shown). Thus tumor size alone cannot be
an indicator of the invasive nature of the small lung
adenocarcinomas.24
On the other hand, subclassification by tumor size might
have an effect on postoperative adjuvant therapy. The stan-
dard of care for resected stage II to IIIA NSCLC now includes
adjuvant chemotherapy based on the results of 3 phase III
studies using cisplatin-based regimens.25–27 However, the
role of adjuvant chemotherapy for stage I disease remains
controversial. Updated results from the Cancer and Leukemia
Group B 9633 trial, the only trial to focus exclusively on pa-
tients with stage IB disease, no longer shows a statistically
significant survival benefit from adjuvant chemotherapy in
this population.28 The patient who would take a survival ben-
efit might be found by the subclassification of current T1 and
T2 tumors in the 2009 system.
Concerning the N classification, the survival rates
decreased as the N number progressed, whereas prognostic
significance was found between N classes in our cohort
(Figure 5).We reported previously that the number of positive
lymph nodes was a strong independent prognostic factor in
patients with resected NSCLCs and could stratify the patients
with N2 disease into a homogenous subgroup.29We hope that
consideration will be given to its inclusion in pathologic stag-
ing in the future. Regarding the lymph node map showing the
sites of nodes, the Japan Lung Cancer Society has produced
theNarukemap,30which is based on bronchial trees, thoracot-
omy findings, and resected specimens, and there is also a map
based on the Mountain–Dresler modification of the map from
the American Thoracic Society,31 which is based on medias-
tinal pleura and mediastinoscopic identification. The 2 maps
have different views on the definition between levels 7 and
10, which causes confusion in the definitions of N1 and N2.
Although the proposal by the IASLC included the ‘‘zone’’
concept, which groups lymph nodes from several nodal sta-
tions, and suggested that this concept also reconciled the
slight differences in nomenclature between the 2 maps,12 dis-
cussion on the issue is still underway.
Figure 5. Survival curves for patient subgroups stratified accord-
ing to N descriptors. The survival curves showed significant step-
wise deterioration as the numbers increased.acic and Cardiovascular Surgery c Volume 136, Number 5 1347
General Thoracic Surgery Fukui et al
G
TSOur study supports the proposals for the new TNM stag-
ing system of lung cancer as reported by the IASLC Staging
Committee. Our survival characteristics of 1556 patients with
resected NSCLCs in a single Japanese institution validated
this proposed staging system, which is based on a large inter-
national database, particularly among patients with patho-
logic stage IA to IIIA disease. In this study patients with
stage IIIB disease showed a worse survival rate than those
with stage IV disease. Because this retrospective study only
included resected cases, the patients with stages III and IV
disease did not represent the whole population of these stage
groups. In any case we should always prepare for future mod-
ifications of the TNM staging system as we gain more knowl-
edge about the biology of lung cancer. Last, we hope to make
the revised staging system easier to remember and less cum-
bersome for clinicians involved in the management of lung
cancer.
We thank Dr Keitaro Matsuo, Division of Epidemiology and
Prevention, Aichi Cancer Center Research Institute, for his advice
on statistical analyses.
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